Fundraising FoxDe Novo Ventures — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupJanus Henderson Investors+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.